Author Archives: Özge Özkaya, PhD

The levels of a protein called calprotectin in the stool could not only be a marker of intestinal disease but could also help determine disease severity in cystic fibrosis (CF), according to a study published in the scientific journal Immunobiology.

Treatment with hyertonic saline administered before airway clearance is no more effective than when administered during airway clearance in cystic fibrosis, found a study published in BMJ Open Respiratory Research.

Bone marrow cells can improve overall lung function and may have potential therapeutic benefits in treating cystic fibrosis, suggests a study published in the journal Molecular Therapy.

Nitrate intake with food can result in an acute but marked increase in the amount of nitric oxide (NO) being exhaled during respiration, suggests a study conducted by researchers in Ireland. This could be important in cystic fibrosis, which is associated with a decreased level of exhaled NO.

A combination therapy with inhaled Bramitob (tobramycin) and Colistin improves lung function and respiratory symptoms in cystic fibrosis (CF) patients, according to a study published in the scientific journal Cellular Physiology and Biochemistry.

A modifier gene called SLC26A9 may have an influence on whether or not cystic fibrosis (CF) patients will respond to treatments with new drugs.

Burkholderia contaminans, a bacteria belonging to the Burkholderia cepacia complex (Bcc) is indeed an opportunistic pathogen in cystic fibrosis according to a study conducted by a team of international researchers.

Spine deformities that are sometimes seen in cystic fibrosis (CF) may be adequately corrected with minimal risk through multidisciplinary care during surgery and meticulous surgical techniques, as reported by a case study reviewed in the article “Scoliosis Surgery in Cystic Fibrosis: Surgical Considerations and the Multidisciplinary Approach of a Rare Case.”

All babies with a known mutation causing cystic fibrosis (CF) and a second mutation known as the 5T allele should be screened for additional mutations to predict their risk of developing CF later in life, according to a study conducted by researchers at Children’s Hospital Los Angeles (CHLA), Brigham and Women’s Hospital (BWH), and the California Department of Public Health.

Nivalis Therapeutics Inc. recently announced that they finished enrolling participants for a Phase 2 clinical trial testing their lead compound N91115 for the treatment of cystic fibrosis (CF).